*ST双成: 海南双成药业股份有限公司2025年半年度业绩预告

Group 1 - The company expects a net loss attributable to shareholders in the range of 13 million to 19 million yuan for the current reporting period, compared to a loss of 16.9462 million yuan in the same period last year, indicating a potential decrease of 12.12% to an increase of 23.29% [1] - The expected operating income for the current period is projected to be between 75 million and 95 million yuan, down from 94.8926 million yuan in the previous year [1] - The company attributes the performance changes to significant price reductions in key products due to market reforms and competitive bidding, particularly affecting domestic sales profits [2] Group 2 - The company has received FDA approval for the abbreviated new drug application (ANDA) for injectable paclitaxel (albumin-bound), which has begun to generate export sales, contributing positively to export profits [2] - Non-recurring gains are expected to contribute approximately 2.55 million yuan to net profit, primarily from government subsidies and investment income [2] - The company is actively taking measures to address the delisting risk warning imposed by the Shenzhen Stock Exchange due to financial performance concerns [3]